Pentoxifylline, ciprofloxacin and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications

Bone Marrow Transplantation

Volumn 20, Issue 12, 1997, Pages 1075-1080

  Ferra C ^a   De Sanjose S ^a   Lastra, C F ^b   Marti F ^a   Marino E L ^b   Sureda, A ^c   Brunet, S ^c   Gallardo, D ^a   Berlanga, J J ^a   Garcia J ^a   Granena A ^a  

^a HOSPITAL DURAN I REYNALS   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Bone marrow transplantation; Ciprofloxacin; Infection; Pentoxifylline; Prednisone; Tumor necrosis factor

Indexed keywords

CIPROFLOXACIN; PENTOXIFYLLINE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ARTICLE; BLOOD CULTURE; BLOOD LEVEL; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DEATH; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INFECTION COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SURVIVAL; SURVIVAL TIME; VEIN OCCLUSION;

EID: 17544394503     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701023     Document Type: Article

References (31)

1. Champlin RE, Gale RP. The early complications of bone marrow transplantation. Semin Hematol 1984; 21: 101-108.
2. Neta R, Sayers TJ, Oppenheim JJ. Relationship of TNF to interleukins. Immunol Ser 1992; 56: 499-566.
3. Holler E, Kolb HJ, Möller A et al. Increased serum levels of tumor necrosis factor α precede major complications of bone marrow transplantation. Blood 1990; 75: 745-750.
4. Chasty RC, Lamb WR, Gallati H et al. Serum cytokine levels in patients undergoing bone marrow transplantation. Bone Marrow Transplant 1993; 12: 331-336.
5. Piguet PF, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of acute graft-versus-host disease. J Exp Med 1987; 166: 1280-1289.
6. Tilg H, Eibl B, Pichl M et al. Immune modulation by pentoxifylline In vitro. Transplantation 1993; 56: 196-201.
7. Vadei K, Brunner LJ, Luke DR. Effects of pentoxifylline in experimental acute renal failure. Kidney Int 1989; 36: 466-470.
8. Bennett WM, Elzinga LW, Porter GA, Rosens S. The effects of pentoxifylline on experimental chronic cyclosporine nephrotoxicity. Transplantation 1992; 54: 1118-1120.
9. Bianco JA, Appelbaum FR, Nemunaitis J et al. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 1991; 78: 1205-1211.
10. Attal M, Huguet F, Rubie H et al. Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective, randomized trial. Blood 1993; 82: 732-736.
11. Clift RA, Bianco FR, Appelbaum CD et al. A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation. Blood 1993; 82: 2025-2030.
12. Beutler B, Krochin N, Milsark I et al. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 1986; 232: 977-980.
13. Bailly S, Fay M, Gougerot-Pocidalo MA. Effet des quinolones sur la production de TNF alpha par les monocytes humains. Patol Biol (Paris) 1990; 38: 267-271.
14. Weinberg JB, Mason SN, Wortham TS. Inhibition of tumor necrosis factor alpha (TNF-α) and interleukin-1b (I-1β) messenger (RNA (m-RNA) expression in HL-60 leukemia cells by pentoxifylline and dexamethasone: dissociation of acividininduced TNFα and IL-1β mRNA expression from acividininduced monocytoid differentation. Blood 1992; 79: 3337-3343.
15. Thompson JA, Benyunes MC, Bianco JA, Fefer A. Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2-activated killer cells. Semin Oncol 1993; 20: 46-51.
16. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
17. McDonald GB, Sharma P, Matthews DE et al. Veno-occlusive disease of the liver after bone marrow transplantation: diagnosis, incidence and predisposing factors. Hepatology 1984; 4: 116-122.
18. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
19. Garnier-Moireaux A, Poirier JM, Cheymol G. High-performance liquid Chromatographic determination of pentoxifylline and its hydroxy-metabolite in human plasma. J Chramatogr Biomed Appl 1987; 416: 183-188.
20. Bianco JA, Nemunaitis J, Lilly M et al. Pentoxifylline (PTX), cyclophosphamide (CY), carmustine (BCNU), and etoposide (VP-16) 'CBV' regimen is an effective bone marrow transplant (BMT) regimen for relapsed lymphoma. Blood 1991; 78: 137a.
21. Bianco JA, Singer JW. Response. Blood 1992; 80: 2683-2684.
22. Kahls P, Lechner K, Stockschläder M et al. Pentoxifylline did not prevent transplant-related toxicity in 31 consecutive allogeneic bone marrow transplant recipients. Blood 1992; 80: 2683.
23. Beelen DW, Sayer HG, Franke M et al. Constant intravenous pentoxifylline infusions in allogeneic marrow transplant recipients: results of a dose escalation study. Bone Marrow Transplant 1993; 12: 363-370.
24. Stockschläder M, Kahls P, Peters S et al. Intravenous pentoxifylline failed to prevent transplant-related toxicities in bone marrow transplant recipients. Bone Marrow Transplant 1993; 12: 357-362.
25. Van der Jagt RHC, Pari G, McDiarmid SA et al. Effect of pentoxifylline on regimen-related toxicity in patients undergoing allogeneic or autologous bone marrow transplantation. Bone Marrow Transplant 1994; 13: 203-207.
26. Bauman H, Richards C, Gauldie J. Interaction among hepatocyte-stimulating factors, interleukin-1, and glucocorticoids for regulation of acute phase plasma proteins in human hepatoma (HepG2) cells. J Immunol 1987; 139: 4122-4128.
27. Bianco JA, Nemunaitis J, Andrews DF et al. Combined therapy with pentoxifylline, ciprofloxacin and prednisone reduces regimen-related toxicity and accelerates engraftment in patients undergoing bone marrow transplantation. Blood 1991; 78: 237a.
28. Sayer G, Longton G, Bowden R et al. Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease. Blood 1994; 84: 1328-1332.
29. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to Viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 1992; 14: 1201-1207.
30. Deeg HJ, Henslee-Downey PJ. Management of acute graft-versus-host disease. Bone Marrow Transplant 1990; 6: 1-8.
31. Hagglünd H, Bopström L, Remberger M et al. Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients. Bone Marrow Transplant 1995; 16: 747-753.